Health Care

Respiri’s (RSH) wheezo device has been given the CE Mark and TGA clearance to be listed in the Australian Therapeutics Goods Register (ARTG).

Biotech company Zoono’s (ZNO) share price is continuing to rise after announcing it has secured an exclusive Chinese distributor for its product which

Starpharma (SPL) has successfully completed the phase 1 component of its phase 1/2 trial for DEP cabazitaxel.

Suda Pharmaceuticals (SUD) and Sanofi-Aventis Groupe have reached an agreement to conduct a feasibility study.

Shares in hemp-pharmaceutical company Creso Pharma (CPH) dipped into the red today — despite entering a new market.

LeMaitre Vascular have placed an order for 12,500 units of Admedus’ (AHZ) CardioCel and VascuCel patches for the year ahead.

Botanix Pharmaceuticals (BOT) has received ethics approval for its planned BTX 1702 Phase 1b study for the treatment of rosacea.

It’s been a big day for digital health engine 1stGroup (1ST), with the launch of the company’s St Vincent’s priority referral platform and

Sienna Cancer Diagnostics (SDX) has raised approximately $1.7 million to accelerate commercialisation of SIEN NET and fund co-development expenditures.

Neuroscientific Biopharmaceuticals (NSB) shares have suffered a mighty blow after some underwhelming results from its latest EmtinB study.